NCI News Releases
04 December 2021
The latest cancer news from the U.S. government's principal agency for cancer research.-
Drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy
A Children’s Oncology Group trial shows that the combination of all-trans retinoic acid and arsenic trioxide is highly effective in children with acute promyelocytic leukemia. The therapy avoids or minimizes the use of conventional chemotherapy.
-
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
NCI researchers have found that adding the targeted therapy ibrutinib (Imbruvica) to standard chemotherapy can improve how long some younger people with a specific form of diffuse large B-cell lymphoma live. The new findings come from a new analysis of a previously conducted phase 3 clinical trial called Phoenix.
-
Annual Report to the Nation Part 2: Patient economic burden of cancer care more than $21 billion in the United States in 2019
Part 2 of the 2021 Annual Report to the Nation on the Status of Cancer, finds that the patient economic burden associated with cancer care in the United States in 2019 was $21.09 billion. This includes patient out-of-pocket costs of $16.22 billion and patient time costs of $4.87 billion.
Feed not found.
